Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for acne
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on acne or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on acne and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Acne treatment and clinical papers
Acne is a common skin condition characterised by whiteheads (or blackheads), pimples and oily skin. It can lead to possible scarring. It is typically caused when hair follicles become inflamed and the sebaceous glands in the skin are overactive. The over production of sebum and a combination of dead skin cells and dirt can clog follicles and pores causing a break out. Acne can affect any age group but it’s more common in adolescents.
There are many ways to treat acne depending on the severity of the case. Treatments include a range of medications such as topical retinoids, antibiotics and in severe cases isotretinoin is prescribed. Research is ongoing to determine the side effects and harms caused by these drugs. Clinical trials and studies are vital to assess treatment.
The Trip Database has an extensive collection of articles on acne ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.
Clascoterone (Winlevi) - acne Drug Approval Package: WINLEVI U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: WINLEVI Company: Cassiopea SpA Application Number: 213433 Approval Date: 8/26/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: September 29, 2020
Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Metformin has been proposed as possibly a safer and more effective long-term treatment than the oral contraceptive pill (OCP) in women with polycystic ovary syndrome (PCOS). It is important to directly compare the efficacy and safety of metformin versus OCP in the long-term treatment of women with PCOS. This is an update of a Cochrane Review comparing insulin
New advice from the MHRA regarding cyproterone acetate: how does this affect prescribing of Co-cyprindiol/Dianette® for acne/hirsutism? July 2020 1 FSRH CEU Statement : New advice from the MHRA regarding cyproterone acetate: how does this affect prescribing of Co-cyprindiol/Dianette ® for acne/hirsutism? 13 July 2020 Background New data from a French cohort study  indicate that use of high dose cyproterone acetate (high dose products contain 50-100mg per tablet) is associated (...) acetate with ethinylestradiol Co-cyprindiol/Dianette ® tablets containing cyproterone acetate with ethinylestradiol are used for treatment of acne and hirsutism in women of reproductive age. In contrast to the high dose products described above, they contain only 2mg of cyproterone acetate; annual cumulative exposure to cyproterone acetate is only about 0.8g. The Yellow Card scheme has received no reports of meningioma associated with use of these low-dose products. The MHRA advises that although
Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne. Acne is an inflammatory disorder with a high global burden. It is common in adolescents and primarily affects sebaceous gland-rich areas. The clinical benefit of the topical acne treatments azelaic acid, salicylic acid, nicotinamide, sulphur, zinc, and alpha-hydroxy acid is unclear.To assess the effects of topical treatments (azelaic acid, salicylic acid, nicotinamide, zinc, alpha (...) -hydroxy acid, and sulphur) for acne.We searched the following databases up to May 2019: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers.Clinical randomised controlled trials of the six topical treatments compared with other topical treatments, placebo, or no treatment in people with acne.We used standard methodological procedures expected by Cochrane. Key outcomes included participants' global self-assessment of acne
Trifarotene (Aklief) - topical treatment of acnevulgaris Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1
Topical benzoyl peroxide for acne. Acne is a common, economically burdensome condition that can cause psychological harm and, potentially, scarring. Topical benzoyl peroxide (BPO) is a widely used acne treatment; however, its efficacy and safety have not been clearly evaluated.To assess the effects of BPO for acne.We searched the following databases up to February 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers (...) and checked the reference lists of relevant randomised controlled trials (RCTs) and systematic reviews.We included RCTs that compared topical BPO used alone (including different formulations and concentrations of BPO) or as part of combination treatment against placebo, no treatment, or other active topical medications for clinically diagnosed acne (used alone or in combination with other topical drugs not containing BPO) on the face or trunk.We used standard methodological procedures as expected
Acnevulgaris: Benzoyl peroxide Benzoyl peroxide | Prescribing information | Acnevulgaris | CKS | NICE Search CKS… Menu Benzoyl peroxide Acnevulgaris: Benzoyl peroxide Last revised in December 2019 Benzoyl peroxide Benzoyl peroxide Indication and dose for acnevulgaris: For Child 12–17 years — apply to the skin 1–2 times a day, preferably after washing with soap and water and start treatment with lower-strength preparations. For Adult — apply to the skin 1–2 times a day, preferably after (...) peroxide is applied at night and the topical antibiotic in the morning. Avoid using two products that both have an alcoholic base as this may increase skin irritation. A combined proprietary product is available. Benzoyl peroxide combined with a topical retinoid is a useful choice, especially in the maintenance of acne. Apply the products once daily, 12 hours apart (for example the topical retinoid at night and benzoyl peroxide in the morning). Both these drugs can irritate the skin; consider using
Acnevulgaris: Azelaic acid Azelaic acid | Prescribing information | Acnevulgaris | CKS | NICE Search CKS… Menu Azelaic acid Acnevulgaris: Azelaic acid Last revised in December 2019 Azelaic acid How should I prescribe azelaic acid? Indication and dose for acnevulgaris For Child 12–17 years — apply twice daily. In people with sensitive skin, apply once daily for 1 week, then apply twice daily. For Adult — apply twice daily. In people with sensitive skin, apply once daily for 1 week
AcnevulgarisAcnevulgaris | Topics A to Z | CKS | NICE Search CKS… Menu AcnevulgarisAcnevulgaris Last revised in December 2019 Acnevulgaris is a chronic skin condition in which blockage or inflammation of the hair follicles and accompanying sebaceous glands Diagnosis Management Prescribing information Background information Acnevulgaris: Summary Acnevulgaris is a chronic inflammatory skin condition affecting mainly the face, back and chest - it is characterised by blockage (...) and inflammation of the pilosebaceous unit (the hair follicle, hair shaft and sebaceous gland). It presents with lesions which can be non-inflammatory (comedones), inflammatory (papules, pustules and nodules) or a mixture of both. Up to 95% of adolescents in Western industrialized countries are affected by acne to some extent — 20 to 35% develop moderate or severe acne. Complications of acne include skin changes such as scarring, post-inflammatory hyperpigmentation or depigmentation and psychosocial problems
Trifarotene (Aklief) - acnevulgaris Drug Approval Package: AKLIEF U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: AKLIEF Company: Galderma Research and Development, LLC Application Number: 211527 Approval Date: 10/04/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF
British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 4 Fitzroy Square, London W1T 5HQ Tel: 020 7383 0266 Fax: 020 7388 5263 e-mail: email@example.com Registered Charity No. 258474 HIDRADENITIS SUPPURATIVA What are the aims of this leaflet? This leaflet has been written to help you understand more about hidradenitis suppurativa (HS). It tells you what it is, what may cause it, what can be done about it, and where you can find out more (...) system is involved in producing inflammation and treatments that reduce the immune system activity may be helpful (see below). ? In a few people with HS there is a link to the bowel condition Crohn ’s disease. ? There may be a link with acne and pilonidal sinus (a chronic abscess at the base of the spine). ? Smoking and obesity are linked with HS, but the condition can also affect non-smokers of normal weight. ? Poor hygiene does not cause hidradenitis suppurativa. Is hidradenitis suppurativa
Acnevulgaris: What else might it be? Differential diagnosis | Diagnosis | Acnevulgaris | CKS | NICE Search CKS… Menu Differential diagnosis Acnevulgaris: What else might it be? Last revised in December 2019 What else might it be? The differential diagnosis for acne includes: Rosacea — for more information, see the CKS topic on . Perioral dermatitis . Folliculitis and boils — for more information, see the CKS topic on . Drug-induced acne — some drugs can cause or exacerbate acneiform (...) eruptions including dioxins (chloracne), corticosteroids, anti-epileptics (phenytoin and carbamazepine), lithium, isoniazid, vitamins B1, B6 and B12. Keratosis pilaris . Basis for recommendation The information on the differential diagnosis of acne is based on clinical guidelines Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne [ ], European evidence-based (S3) guideline for the treatment of acne – update 2016 [ ], Guidelines of care for the management of acnevulgaris
Acnevulgaris: Topical retinoids Topical retinoids | Prescribing information | Acnevulgaris | CKS | NICE Search CKS… Menu Topical retinoids Acnevulgaris: Topical retinoids Last revised in December 2019 Topical retinoids Topical retinoids Indication and dose for mild to moderate acnevulgaris Adapalene and tretinoin are the topical retinoids licenced for use in children over the age of 12 and adults in the UK. Topical isotretinoin is licenced for use in adults only. Application is usually (...) once or twice a day and varies between agents — for information on specific products see the (BNF) and the . If peeling due to use of other irritant acne treatments is present, allow to subside before starting a topical retinoid — discontinue use if severe irritation occurs. Topical retinoids should be used sparingly to cover the whole affected area and not just on visible spots — if the person has sensitive skin, initiate therapy at a lower frequency (for example three times per week) and increase
Acnevulgaris: Oral antibiotics Oral antibiotics | Prescribing information | Acnevulgaris | CKS | NICE Search CKS… Menu Oral antibiotics Acnevulgaris: Oral antibiotics Last revised in December 2019 Oral antibiotics Oral antibiotics Prescribing issues If acne fails to respond adequately to topical preparations alone an oral antibiotic such as lymecycline or doxycycline (for a maximum of 3 months) can be added. Minocycline is not recommended for use in acne as it is associated (...) with an increased risk of adverse effects such as drug-induced lupus, skin pigmentation and hepatitis. Macrolide antibiotics (such as erythromycin) should generally be avoided due to high levels of P. acnes resistance but can be used if tetracyclines are contraindicated (for example in pregnancy). A topical retinoid (if not contraindicated) or benzoyl peroxide should always be co-prescribed with oral antibiotics to reduce the risk of antibiotic resistance developing. Do not use topical and oral antibiotics
Acnevulgaris: How should I assess a person with suspected acnevulgaris? Assessment | Diagnosis | Acnevulgaris | CKS | NICE Search CKS… Menu Assessment Acnevulgaris: How should I assess a person with suspected acnevulgaris? Last revised in December 2019 How should I assess a person with suspected acnevulgaris? Take a history asking about: Duration, type and distribution of lesions. Previous treatment (including over-the-counter medications) and response. Exacerbating factors (...) guidelines Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne [ ]. Management of acne: Canadian clinical practice guideline [ ], A consensus-based practical and daily guide for the treatment of acne patients [ ], European evidence-based (S3) guideline for the treatment of acne – update 2016 [ ], Guidelines of care for the management of acnevulgaris [ ], and Acne: acnevulgaris [ ], and expert opinion in review articles [ ; ; ; ]. Ask about psychosocial impact Acne
Acnevulgaris: Scenario: Management of acnevulgaris in primary care Scenario: Primary care management | Management | Acnevulgaris | CKS | NICE Search CKS… Menu Scenario: Primary care management Acnevulgaris: Scenario: Management of acnevulgaris in primary care Last revised in December 2019 Scenario: Management of acnevulgaris in primary care From age 12 years onwards. How should I manage a person with acnevulgaris in primary care? Explain the diagnosis and provide patient information (...) -based practical and daily guide for the treatment of acne patients [ ], European evidence-based (S3) guideline for the treatment of acne – update 2016 [ ], Guidelines of care for the management of acnevulgaris [ ], and Acne: acnevulgaris [ ], and expert opinion in review articles [ ; ; ; ; ; ; ; ; ]. General advice Cleansing — Acne is not caused by poor hygiene. Aggressive washing can aggravate acne and should be avoided [ ; ; ]. Healthy diet — The role of diet in acne remains poorly understood
Sarecycline (Seysara) - To treat inflammatory lesions of non-nodular moderate to severe acnevulgaris in patients 9 years of age and older Drug Approval Package: Seysara (sarecycline) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Seysara (sarecycline) Company: Allergan, Inc. Application Number: 209521 Approval Date: 10/01/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA